Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.5.1.3 (
dihydrofolate reductase
)
5,819
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mutations in
AIPL1
cause the inherited blindness Leber congenital amaurosis (LCA).
AIPL1
has previously been shown to interact with NUB1, which facilitates the proteasomal degradation of proteins modified with the ubiquitin-like protein FAT10. Here we report that
AIPL1
binds non-covalently to free FAT10 and FAT10ylated proteins and can form a ternary complex with FAT10 and NUB1. In addition,
AIPL1
antagonised the NUB1-mediated degradation of the model FAT10 conjugate, FAT10-
DHFR
, and pathogenic mutations of
AIPL1
were defective in inhibiting this degradation. While all
AIPL1
mutants tested still bound FAT10-
DHFR
, there was a close correlation between the ability of the mutants to interact with NUB1 and their ability to prevent NUB1-mediated degradation. Interestingly,
AIPL1
also co-immunoprecipitated the E1 activating enzyme for FAT10, UBA6, suggesting
AIPL1
may have a role in directly regulating the FAT10 conjugation machinery. These studies are the first to implicate FAT10 in retinal cell biology and LCA pathogenesis, and reveal a new role of
AIPL1
in regulating the FAT10 pathway.
...
PMID:The inherited blindness protein AIPL1 regulates the ubiquitin-like FAT10 pathway. 2234 7